Spruce Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Spruce Biosciences, Inc. (SPRB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $871.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $871.00K.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $689.00K, a 26.65% increase year-over-year.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.69M, a 76.07% increase year-over-year.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $415.00K, a 63.60% decline year-over-year.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.57M, a 51.87% decline from fiscal 2024.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.35M, a 15.71% increase from fiscal 2023.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.62M, a 27.29% increase from fiscal 2022.
- Spruce Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.63M, a 8.26% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $871.00K 10-Q · filed 2026-08-12 | $1.56M 10-Q · filed 2026-08-12 | $3.25M derived: sum of 3 quarters · filed 2026-08-12 | $3.67M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $689.00K 10-Q · filed 2026-05-13 | $2.38M derived: sum of 2 quarters · filed 2026-05-13 | $2.80M derived: sum of 3 quarters · filed 2026-05-13 | $2.72M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.11M derived: sum of 2 quarters · filed 2026-03-09 | $2.03M derived: sum of 3 quarters · filed 2026-08-12 | $2.57M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $415.00K 10-Q · filed 2025-11-10 | $338.00K derived: sum of 2 quarters · filed 2026-08-12 | $882.00K 10-Q · filed 2025-11-10 | $1.84M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$77.00K 10-Q · filed 2026-08-12 | -$467.00K 10-Q · filed 2026-08-12 | $467.00K 10-Q · filed 2025-08-14 | $1.43M derived: sum of 3 quarters · filed 2026-08-12 | $2.57M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $544.00K 10-Q · filed 2026-05-13 | $1.50M derived: sum of 2 quarters · filed 2026-05-13 | $2.65M derived: sum of 3 quarters · filed 2026-05-13 | $4.33M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $961.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.10M derived: sum of 2 quarters · filed 2026-03-09 | $3.79M derived: sum of 3 quarters · filed 2026-03-09 | $5.35M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $1.14M 10-Q · filed 2025-11-10 | $2.83M derived: sum of 2 quarters · filed 2025-11-10 | $4.39M 10-Q · filed 2025-11-10 | $5.61M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $1.69M 10-Q · filed 2025-08-14 | $3.25M 10-Q · filed 2025-08-14 | $4.47M derived: sum of 3 quarters · filed 2025-08-14 | $5.59M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $1.56M 10-Q · filed 2025-05-06 | $2.78M derived: sum of 2 quarters · filed 2025-05-06 | $3.90M derived: sum of 3 quarters · filed 2025-05-06 | $5.12M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $2.34M derived: sum of 2 quarters · filed 2025-04-15 | $3.56M derived: sum of 3 quarters · filed 2025-04-15 | $4.62M 10-K · filed 2025-04-15 | |
| 2023-09-30 | $1.12M 10-Q · filed 2024-11-12 | $2.34M derived: sum of 2 quarters · filed 2024-11-12 | $3.40M 10-Q · filed 2024-11-12 | $4.20M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.22M 10-Q · filed 2024-08-12 | $2.28M 10-Q · filed 2024-08-12 | $3.08M derived: sum of 3 quarters · filed 2024-08-12 | $3.86M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $1.06M 10-Q · filed 2024-05-13 | $1.86M derived: sum of 2 quarters · filed 2024-05-13 | $2.65M derived: sum of 3 quarters · filed 2024-05-13 | $3.55M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $1.58M derived: sum of 2 quarters · filed 2024-03-18 | $2.49M derived: sum of 3 quarters · filed 2024-03-18 | $3.63M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $783.00K 10-Q · filed 2023-11-13 | $1.69M derived: sum of 2 quarters · filed 2023-11-13 | $2.83M 10-Q · filed 2023-11-13 | $3.63M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $905.00K 10-Q · filed 2023-08-14 | $2.05M 10-Q · filed 2023-08-14 | $2.84M derived: sum of 3 quarters · filed 2023-08-14 | $3.87M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.14M 10-Q · filed 2023-05-15 | $1.94M derived: sum of 2 quarters · filed 2023-05-15 | $2.97M derived: sum of 3 quarters · filed 2023-05-15 | $3.98M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.83M derived: sum of 2 quarters · filed 2023-03-16 | $2.84M derived: sum of 3 quarters · filed 2023-03-16 | $3.96M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $1.03M 10-Q · filed 2022-11-10 | $2.04M derived: sum of 2 quarters · filed 2022-11-10 | $3.16M 10-Q · filed 2022-11-10 | $3.57M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.01M 10-Q · filed 2022-08-10 | $2.13M 10-Q · filed 2022-08-10 | $2.54M derived: sum of 3 quarters · filed 2022-08-10 | $2.76M derived: sum of 4 quarters · filed 2022-08-10 | |
| 2021-03-31 | $1.12M 10-Q · filed 2022-05-11 | $1.53M derived: sum of 2 quarters · filed 2022-05-11 | $1.75M derived: sum of 3 quarters · filed 2022-05-11 | $1.84M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $627.00K derived: sum of 2 quarters · filed 2022-03-14 | $723.00K derived: sum of 3 quarters · filed 2022-03-14 | $755.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $218.00K 10-Q · filed 2021-11-15 | $314.00K derived: sum of 2 quarters · filed 2021-11-15 | $346.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $96.00K 10-Q · filed 2020-11-18 | $128.00K 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $32.00K 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | $196.00K 10-K · filed 2021-03-22 | ||||
| 2019-09-30 | $62.00K 10-Q · filed 2020-11-18 | $139.00K derived: sum of 2 quarters · filed 2020-11-18 | $154.00K derived: sum of 3 quarters · filed 2020-11-18 | ||
| 2019-06-30 | $77.00K 10-Q · filed 2020-11-18 | $92.00K derived: sum of 2 quarters · filed 2020-11-18 | |||
| 2019-03-31 | $15.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |